Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia

Journal of Clinical Oncology

Volumn 25, Issue 1, 2007, Pages 10-15

  Roboz, Gail J ^a   Giles, Francis J ^a   Ritchie, Ellen K ^a   Allen Bard, Sandra ^a   Curcio, Tania J ^a   Wilkes, Meredith A ^a   Park, S Lani ^a   Kantarjian, Hagop M ^a   Faderl, Stefan ^a   Ravandi, Farhad ^a   Kelner, Michael J ^a   Feldman, Eric J ^a  

^a Department of Obstetrics Gynecology

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE PATCH; PREDNISONE; TROXACITABINE; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOSINE; DRUG DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTEREMIA; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DESQUAMATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; MACULOPAPULAR RASH; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME; ADOLESCENT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTOSINE; DIOXOLANES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548533162     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.6209     Document Type: Article

References (15)

1. Giles FJ: Troxacitabine-based therapy of refractory leukemia. Expert Rev Anticancer Ther 2:261-266, 2002
2. Giles FJ, Cortes JE, Baker SD, et al: Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 19:762-771, 2001
3. Giles FJ, Faderl S, Thomas DA, et al: Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 21:1050-1056, 2003
4. Giles FJ, Feldman EJ, Roboz GJ, et al: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myeloid leukemia in blastic phase. Leuk Res 27:1091-1096, 2003
5. Giles FJ, Garcia-Manero G, Cortes JE, et al: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 20:656-664, 2002
6. Giles FJ, Kantarjian HM, Cortes JE, et al: Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21:1722-1727, 2003
7. Alvarado Y, Kantarjian HM, Cortes JE, et al: Troxacitabine activity in extramedullary myeloid leukemia. Hematology 7:179-185, 2002
8. Gourdeau H, Clarke ML, Ouellet F, et al: Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 61:7217-7224, 2001
9. Giles FJ: Novel agents for the therapy of acute leukemia. Curr Opin Oncol 14:3-9, 2002
10. Gourdeau H, Genne P, Kadhim S, et al: Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Cancer Chemother Pharmacol 50:490-496, 2002
11. Gourdeau H, Bibeau L, Ouellet F, et al: Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol 47:236-240, 2001
12. Gourdeau H, Leblond L, Hamelin B, et al: Species differences in troxacitabine pharmacokinetics and pharmacodynamics: Implications for clinical development. Clin Cancer Res 10:7692-7702, 2004
13. Kadhim SA, Bowlin TL, Waud WR, et al: Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 57:4803-4910, 1997
14. Giles FJ, Keating A, Goldstone AH, et al: Acute myeloid leukemia, in, Hematology. Washington, DC, American Society of Hematology, 2002, pp 73-110
15. Giles FJ, O'Brien S, Cortes J, et al: Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 104:547-554, 2005